RhumbLine Advisers
CTNM

RhumbLine Advisers’s Contineum Therapeutics CTNM Stock Holding History

RhumbLine Advisers’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$510K Buy
+31,098
New +$408K ﹤0.01% 2758
2025
Q2 		– Sell
-7,573
Closed -$52.9K – 4290
2025
Q1 		$52.9K Sell
7,573
-660
-8% -$6K ﹤0.01% 3560
2024
Q4 		$121K Buy
8,233
+2,191
+36% +$34.7K ﹤0.01% 3420
2024
Q3 		$116K Sell
6,042
-680
-10% -$13K ﹤0.01% 3460
2024
Q2 		$118K Buy
+6,722
New +$108K ﹤0.01% 3465

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers's CTNM Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 31,098 shares worth $510K. The stake represents ﹤0.01% of the portfolio and ranks #2758 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in CTNM as recently as Q1 2025.

RhumbLine Advisers first reported a position in CTNM in Q2 2024 and has held it in 5 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • RhumbLine Advisers held 31,098 shares of Contineum Therapeutics worth $510K as of Q2 2026.
  • Contineum Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Contineum Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2758 holding.
  • RhumbLine Advisers first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.